MOU Signed with Ceragem Clinical, Aimed, and Aimnext
Strengthening Sleep Tech Business Following Launch of Insomnia Diagnostic Solution
On May 22, Ybrain, an electroceutical platform company, announced that it had signed a four-party business agreement to jointly distribute the digital insomnia treatment (DTx) Somz. Through this agreement, Ybrain plans to actively promote the distribution and sales of Somz to psychiatry and neurology clinics.
On the 22nd, to expand the distribution of the digital insomnia treatment Somz, Ybrain, Ceragem Clinical, Aimed, and Aimnext signed a four-party MOU. Ybrain
The agreement involves a total of four companies: Ybrain, Ceragem Clinical, Aimed, and Aimnext. These companies plan to identify joint business opportunities and expand mutual cooperation in various digital healthcare fields, including insomnia treatment, wellness enhancement, fertility improvement, and senior and home care.
Through this agreement, Ybrain has entered into a strategic distribution partnership to expand the mental health market for Somz, Aimnext’s digital therapeutic device, and will also collaborate on joint research and development of sleep wellness solutions and programs.
Ceragem Clinical, based on its bed-type medical device platform, will work with Aimnext to promote a B2C (business-to-consumer) wellness product business aimed at improving sleep and fertility.
Recently, Ybrain launched the Mind Digital Sleep Diary, an insomnia diagnostic solution, and is further strengthening its business in the sleep tech sector through the distribution agreement for Somz. Kiwon Lee, CEO of Ybrain, stated, "Among experts, the importance of cognitive behavioral therapy in the actual treatment of patients diagnosed with insomnia is highly emphasized," adding, "We expect to support the real recovery of insomnia patients through infrastructure that can connect diagnosis and treatment within hospitals."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
